PURPOSE: The concentrative amino acid transporter ATB(0,+) (SLC6A14) is under evaluation as a target for anticancer therapy. An ATB(0,+)-selective positron emission tomography (PET) probe could advance preclinical drug development. We characterised the cationic tyrosine analogue O-2((2-[(18)F]fluoroethyl)methyl-amino)ethyltyrosine ([(18)F]FEMAET) as a PET probe for ATB(0,+) activity. PROCEDURES: Cell uptake was studied in vitro. ATB(0,+) expression was quantified by real-time PCR. [(18)F]FEMAET accumulation in xenografts was investigated by small animal PET with mice. RESULTS: [(18)F]FEMAET accumulated in PC-3 and NCI-H69 cancer cells in vitro. As expected for ATB(0,+) transport, uptake was inhibited by LAT/ATB(0,+) inhibitors and dibasic amino acids, and [(18)F]FEMAET efflux was only moderately stimulated by extracellular amino acids. ATB(0,+) was expressed in PC-3 and NCI-H69 but not MDA-MB-231 xenografts. PET revealed accumulation in PC-3 and NCI-H69 xenografts and significant reduction by ATB(0,+) inhibition. Uptake was negligible in MDA-MB-231 xenografts. CONCLUSION: ATB(0,+) activity can be imaged in vivo by PET with [(18)F]FEMAET.
PURPOSE: The concentrative amino acid transporter ATB(0,+) (SLC6A14) is under evaluation as a target for anticancer therapy. An ATB(0,+)-selective positron emission tomography (PET) probe could advance preclinical drug development. We characterised the cationic tyrosine analogue O-2((2-[(18)F]fluoroethyl)methyl-amino)ethyltyrosine ([(18)F]FEMAET) as a PET probe for ATB(0,+) activity. PROCEDURES: Cell uptake was studied in vitro. ATB(0,+) expression was quantified by real-time PCR. [(18)F]FEMAET accumulation in xenografts was investigated by small animal PET with mice. RESULTS: [(18)F]FEMAET accumulated in PC-3 and NCI-H69 cancer cells in vitro. As expected for ATB(0,+) transport, uptake was inhibited by LAT/ATB(0,+) inhibitors and dibasic amino acids, and [(18)F]FEMAET efflux was only moderately stimulated by extracellular amino acids. ATB(0,+) was expressed in PC-3 and NCI-H69 but not MDA-MB-231 xenografts. PET revealed accumulation in PC-3 and NCI-H69 xenografts and significant reduction by ATB(0,+) inhibition. Uptake was negligible in MDA-MB-231 xenografts. CONCLUSION:ATB(0,+) activity can be imaged in vivo by PET with [(18)F]FEMAET.
Authors: O A Ryazanova; I M Voloshin; V L Makitruk; V N Zozulya; V A Karachevtsev Journal: Spectrochim Acta A Mol Biomol Spectrosc Date: 2006-07-26 Impact factor: 4.098
Authors: Naren Gupta; Seiji Miyauchi; Robert G Martindale; Anne V Herdman; Robert Podolsky; Katsuya Miyake; Sela Mager; Puttur D Prasad; Malliga E Ganapathy; Vadivel Ganapathy Journal: Biochim Biophys Acta Date: 2005-06-30
Authors: Giuseppe Pandini; Marco Genua; Francesco Frasca; Sebastiano Squatrito; Riccardo Vigneri; Antonino Belfiore Journal: Cancer Res Date: 2007-09-15 Impact factor: 12.701
Authors: Oliver C Neels; Klaas P Koopmans; Pieter L Jager; Laya Vercauteren; Aren van Waarde; Janine Doorduin; Hetty Timmer-Bosscha; Adrienne H Brouwers; Elisabeth G E de Vries; Rudi A J O Dierckx; Ido P Kema; Philip H Elsinga Journal: Cancer Res Date: 2008-09-01 Impact factor: 12.701
Authors: V Coothankandaswamy; S Cao; Y Xu; P D Prasad; P K Singh; C P Reynolds; S Yang; J Ogura; V Ganapathy; Y D Bhutia Journal: Br J Pharmacol Date: 2016-10-18 Impact factor: 8.739
Authors: Alan R Penheiter; Sibel Erdogan; Stephen J Murphy; Steven N Hart; Joema Felipe Lima; Fariborz Rakhshan Rohakhtar; Daniel R O'Brien; William R Bamlet; Ryan E Wuertz; Thomas C Smyrk; Fergus J Couch; George Vasmatzis; Claire E Bender; Stephanie K Carlson Journal: Biomed Res Int Date: 2015-05-27 Impact factor: 3.411